Citation Impact
Citing Papers
Patterns of Gene Expression and Copy-Number Alterations in von-Hippel Lindau Disease-Associated and Sporadic Clear Cell Carcinoma of the Kidney
2009 StandoutNobel
Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)
2012
Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)
2012
Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
2010
Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: Developmental culling and cancer
2005 StandoutNobel
Treatment of kidney cancer
2009 StandoutNobel
Hypoxia-Inducible Factor-1-Dependent Repression of E-cadherin in von Hippel-Lindau Tumor Suppressor–Null Renal Cell Carcinoma Mediated by TCF3, ZFHX1A, and ZFHX1B
2006 StandoutNobel
Hypoxia-Inducible Factor Linked to Differential Kidney Cancer Risk Seen with Type 2A and Type 2B VHL Mutations
2007 StandoutNobel
The DNA-damage response in human biology and disease
2009 StandoutNature
EGFR Antagonists in Cancer Treatment
2008 Standout
pVHL Acts as an Adaptor to Promote the Inhibitory Phosphorylation of the NF-κB Agonist Card9 by CK2
2007 StandoutNobel
Hepatocellular carcinoma
2018 Standout
The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review
2006
Free radicals, metals and antioxidants in oxidative stress-induced cancer
2006 Standout
Reactive oxygen species and antioxidant machinery in abiotic stress tolerance in crop plants
2010 Standout
Prodrug Strategies in Anticancer Chemotherapy
2007
HIF2α cooperates with RAS to promote lung tumorigenesis in mice
2009 StandoutNobel
VHL and p53: Tumor Suppressors Team Up to Prevent Cancer
2006 StandoutNobel
Rapid translocation of nanoparticles from the lung airspaces to the body
2010 StandoutNobel
Nanocarriers as an emerging platform for cancer therapy
2007 Standout
Inhibition of angiogenesis and invasion in malignant gliomas
2007
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
2007
Myeloid-derived suppressor cells as regulators of the immune system
2009 Standout
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
2006
Defective Differentiation of Myeloid and Plasmacytoid Dendritic Cells in Advanced Cancer Patients is not Normalized by Tyrosine Kinase Inhibition of the Vascular Endothelial Growth Factor Receptor
2007
Polymer conjugates as anticancer nanomedicines
2006 Standout
Reactive oxygen species (ROS) as pleiotropic physiological signalling agents
2020 Standout
Design considerations for tumour-targeted nanoparticles
2009 StandoutNobel
Angiogenesis in life, disease and medicine
2005 StandoutNature
The 6‐maleimidocaproyl hydrazone derivative of doxorubicin (DOXO‐EMCH) is superior to free doxorubicin with respect to cardiotoxicity and mitochondrial damage
2006
Failure to prolyl hydroxylate hypoxia‐inducible factor α phenocopies VHL inactivation in vivo
2006 StandoutNobel
Fluorescent Nanorods and Nanospheres for Real‐Time In Vivo Probing of Nanoparticle Shape‐Dependent Tumor Penetration
2011 StandoutNobel
Malignant Gliomas in Adults
2008 Standout
Angiogenesis in brain tumours
2007
Heterogeneous Effects of Direct Hypoxia Pathway Activation in Kidney Cancer
2015 StandoutNobel
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
2015 Standout
Free radicals and antioxidants in normal physiological functions and human disease
2006 Standout
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
2012 Standout
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
2010 Standout
Biomarkers of response and resistance to antiangiogenic therapy
2009
Primary brain tumours in adults
2012 Standout
Basic and Therapeutic Aspects of Angiogenesis
2011 Standout
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
2008 Standout
Ras, PI(3)K and mTOR signalling controls tumour cell growth
2006 StandoutNature
Predicting benefit from anti-angiogenic agents in malignancy
2006
Molecular mechanisms and clinical applications of angiogenesis
2011 StandoutNature
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Metal-induced oxidative stress and signal transduction
2004
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Tumor Angiogenesis
2008 Standout
Hepatocellular carcinoma
2022 Standout
HIF-1α is required for development of the sympathetic nervous system
2019 StandoutNobel
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
2010
Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer
2009
Emerging nanomedicine approaches fighting tumor metastasis: animal models, metastasis-targeted drug delivery, phototherapy, and immunotherapy
2016
Therapeutic Application of Noncytotoxic Molecular Targeted Therapy in Gliomas: Growth Factor Receptors and Angiogenesis Inhibitors
2008
Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
2012
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Functional Nanomaterials for Phototherapies of Cancer
2014 Standout
Nanoparticles in Photodynamic Therapy
2015 Standout
Antiangiogenics: The Potential Role of Integrating This Novel Treatment Modality With Chemoradiation for Solid Cancers
2007
pVHL suppresses kinase activity of Akt in a proline-hydroxylation–dependent manner
2016 StandoutScienceNobel
Multistage nanoparticle delivery system for deep penetration into tumor tissue
2011 StandoutNobel
Randomized, Placebo-Controlled, Phase III Study of Oxaliplatin, Fluorouracil, and Leucovorin With or Without PTK787/ZK 222584 in Patients With Previously Treated Metastatic Colorectal Adenocarcinoma
2011
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy
2007
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma
2007 StandoutNobel
Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma
2011
Albumin-Binding Prodrugs of Camptothecin and Doxorubicin with an Ala-Leu-Ala-Leu-Linker That Are Cleaved by Cathepsin B: Synthesis and Antitumor Efficacy
2007
Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin
2007
Tissue- and Organ-Selective Biodistribution of NIR Fluorescent Quantum Dots
2009 StandoutNobel
Hypoxia and HIF1α Repress the Differentiative Effects of BMPs in High-Grade Glioma
2008
Role ofVHLGene Mutation in Human Cancer
2004 StandoutNobel
Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates
2008
Works of Michael Medinger being referenced
Receptor Tyrosine Kinases: The Main Targets for New Anticancer Therapy
2003
Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials
2005
Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours
2005
Phase I dose-escalation study of the highly potent VEGF receptor kinase inhibitor, AZD2171, in patients with advanced cancers with liver metastases
2004
Phase I dose escalating study of PEG-PGA and DON (GlutaDON): A new amino acid depleting anti cancer drug approach
2004
Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors
2005
Phase I dose-escalation and pharmacokinetic (PK) study of a(6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH) in patients with advanced cancers
2004
Phase I dose-escalation and pharmacokinetic (PK) study of a(6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH) in patients with advanced cancers
2004
Phase I dose-escalation study of the highly potent VEGF receptor kinase inhibitor, AZD2171, in patients with advanced cancers with liver metastases
2004
Phase I and Pharmacokinetic Study of the (6-Maleimidocaproyl)Hydrazone Derivative of Doxorubicin
2007
Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors
2007